Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Rhea-AI Summary

Psyence BioMed (NASDAQ: PBM) announced that its strategic investment in PsyLabs builds a vertically integrated, GMP-compliant pharmaceutical platform supporting psilocybin and ibogaine development.

PsyLabs is licensed, debt-free, and exported its first clinical-trial product to Australia, while the company reports no corporate debt and a focus on disciplined capital allocation.

Positive

• PsyLabs completed export of its first clinical-trial product to Australia, demonstrating operational readiness
• GMP-compliant production capability for both psilocybin and ibogaine
• Company reports a capital structure with no corporate debt
• Vertically integrated manufacturing plus analytical labs reduce execution risk and support clinical continuity

Negative

• None.

Key Figures

Psychedelic drugs market size: $8.75 billion Market CAGR: 13.55% Hospital distribution share: nearly 60% +1 more

4 metrics

Psychedelic drugs market size $8.75 billion Projected global market by 2031

Market CAGR 13.55% Projected CAGR for psychedelic drugs market to 2031

Hospital distribution share nearly 60% Hospital pharmacies’ share of psychedelic drug distribution in 2025

Publication date March 11, 2026 Date of corporate update on PsyLabs and management changes

Market Reality Check

Price: $2.51 Vol: Volume 29,303 is light at...

low vol

$2.51 Last Close

Volume Volume 29,303 is light at 0.13x the 20-day average of 229,437 ahead of this update. low

Technical Shares at $2.51 are trading well below the 200-day MA of $18.49, reflecting a prolonged downtrend.

Peers on Argus

PBM’s -1.57% move contrasts with mixed biotech peers: SLRX +18.98%, PTIX +8.91%,...

1 Up

PBM’s -1.57% move contrasts with mixed biotech peers: SLRX +18.98%, PTIX +8.91%, SCNI +6.88%, while GTBP -2.71% and VRAX -1.17% declined. Peer momentum data only flags GTBP moving up, suggesting today’s setup is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	Clinical supply update	Positive	+3.5%	Export of GMP-manufactured NPX-5 to supply Phase IIb trial in Australia.
Feb 20	Equity investment	Negative	-10.8%	PsyLabs put option exercise leading to US$5M share-for-share equity investment.
Feb 17	Shareholder meeting	Negative	-9.7%	Approval of director slate, auditors, and potential share consolidations up to 250:1.
Feb 13	Supply agreement	Negative	-9.7%	Approval of put option with PsyLabs to secure GMP psilocybin and ibogaine supply.
Feb 11	Litigation settlement	Negative	-6.9%	Settlement of KAOS Capital shareholder claim with US$1.5M payment and share sale terms.

Pattern Detected

Recent PBM news has generally led to negative price reactions, including corporate actions and litigation, with only the psilocybin export update drawing a positive move.

Recent Company History

Over the last few months, PBM has issued several material updates. On Feb 11, 2026, it settled shareholder litigation with a -6.92% reaction. A put option agreement with PsyLabs on Feb 13, 2026 and subsequent shareholder meeting results on Feb 17, 2026 both coincided with -9.71% moves. The Feb 20, 2026 strategic equity investment in PsyLabs saw a -10.8% reaction. In contrast, the Mar 3, 2026 export of GMP psilocybin for an ongoing Phase IIb trial produced a modest +3.52% gain.

Market Pulse Summary

This announcement emphasizes PBM’s alignment with PsyLabs to secure GMP-compliant psilocybin and ibo...

Analysis

This announcement emphasizes PBM’s alignment with PsyLabs to secure GMP-compliant psilocybin and ibogaine manufacturing, export readiness, and support for an ongoing Phase IIb palliative-care trial. It also highlights a debt-free capital structure, disciplined equity issuance, and a management change effective February 20, 2026. In the months leading up to this, PBM addressed litigation, capital-structure flexibility, and strategic supply agreements. Investors following this story may watch for further clinical data, commercialization milestones, and execution against the infrastructure-focused strategy.

Key Terms

gmp-compliant, intellectual property, phase iib, cagr, +3 more

7 terms

gmp-compliant technical

"GMP-compliant manufacturing capabilities."

Good Manufacturing Practice (GMP) compliant means a maker follows established, inspectable rules for producing medicines, medical devices, or other regulated products so each batch is safe, consistent and of expected quality. For investors, GMP compliance lowers the chance of regulatory shutdowns, recalls or delays and increases the likelihood products can be sold; think of it as a verified recipe and checklist that keeps a factory from making faulty batches.

intellectual property regulatory

"Intellectual property protection."

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

phase iib medical

"ongoing Phase IIb trial for adjustment disorder in palliative care."

Phase IIb is a mid-stage clinical trial that tests whether an experimental treatment works and what dose is best by studying it in a larger group of patients than early tests. For investors, Phase IIb results are important because they substantially reduce uncertainty about a drug’s effectiveness and safety, and positive or negative outcomes often drive company valuation, partnership interest, and the likelihood of advancing to the large, costly Phase III trials.

cagr financial

"projected to reach $8.75 billion by 2031, growing at a CAGR of 13.55%"

Compound Annual Growth Rate (CAGR) measures the average yearly growth of an investment, revenue, or other metric over a multi-year period as if it had grown at a steady rate each year. Think of it like the constant speed that would take you from the starting value to the ending value over the same time—useful because it smooths out ups and downs and lets investors compare different assets or performance periods on an even footing.

controlled substance regulatory

"knowledge of international controlled substance regulatory frameworks"

A controlled substance is a drug or chemical whose manufacture, possession, use and distribution are restricted by government law because of potential for abuse, addiction or harm. For investors it matters because these rules shape a company’s ability to sell products, obtain licenses, win approvals and avoid fines or criminal risk — like a speed limit that constrains how fast a business can grow or exposes it to penalties if violated.

psilocybin medical

"governmentally licensed psilocybin cultivation and production facilities"

A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.

ibogaine medical

"Source-level ibogaine supply."

A naturally derived psychoactive compound used experimentally to treat substance use disorders and certain mental health conditions; it acts on the brain to reduce cravings and withdrawal symptoms. Investors care because a successful, approved therapy could open a new treatment market, while safety concerns, mixed clinical evidence, and strict regulatory oversight create high development risk—think of it as an experimental key that may unlock value but must pass several safety locks first.

AI-generated analysis. Not financial advice.

“The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today reinforced how its strategic investment in PsyLabs strengthens its control over pharmaceutical-grade manufacturing and commercial supply chain infrastructure – a critical differentiator in the rapidly expanding psychedelic pharmaceutical sector.

Through its investment in PsyLabs, Psyence BioMed has secured:

• A licensed, owned, and debt-free production operation.
• Source-level ibogaine supply.
• Natural psilocybin supply.
• GMP-compliant manufacturing capabilities.
• Intellectual property protection.
• Integrated analytical and chemistry laboratory infrastructure.
• A capital structure with no corporate debt.

As the psychedelic therapeutics sector matures, scalable pharmaceutical-grade manufacturing has become one of the most significant barriers to entry. PsyLabs operates fully compliant production and laboratory facilities capable of supplying pharmaceutical-grade natural compounds at scale, positioning Psyence BioMed with infrastructure built for sustained execution and long-term competitiveness.

The recent export of PsyLabs’ first clinical trial product to Australia supports the Company's belief this vertically integrated model is operational and commercially ready. By controlling manufacturing, quality, and regulatory supply, the Company materially reduces execution risk while strengthening commercialization preparedness. This alignment of GMP-compliant product supply with clinical expertise directly supports the generation of real-world validation data through its ongoing Phase IIb trial for adjustment disorder in palliative care.

Facility and laboratory operations can be viewed here:

PsyLabs Laboratory: https://vimeo.com/992901896/2d6ff7e8b9
PsyLabs Production Facility: https://vimeo.com/1007910372?fl=ip&fe=ec

A Disciplined Capital Allocation Strategy

Psyence BioMed operates with a disciplined capital allocation framework centered on long-term value creation and operational integrity. The Company prioritizes investment in clinical advancement, manufacturing infrastructure, and operational execution over promotional spending. Equity issuance is undertaken only when strategically accretive, executive compensation is aligned with performance, and financing decisions are structured to avoid unnecessary dilution or burdensome debt. This approach reflects a commitment to financial stewardship, balance sheet strength, and sustainable growth.

“Our responsibility is to be disciplined custodians of shareholder capital,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “We are focused on building infrastructure, advancing our programs, and strengthening our manufacturing alignment. Sustainable growth comes from fundamentals – not promotion.”

This disciplined foundation supports the Company’s broader objective: building a durable pharmaceutical enterprise designed for long-term impact. Psyence BioMed is focused on strengthening its team, partners, and ecosystem, recognizing that enduring success is shared. The Company places equal importance on delivering shareholder returns and advancing therapies that positively impact patients and communities, including the development of a compassionate pricing framework to support fair and responsible access as commercialization progresses.

Market Dynamics Favor Pharmaceutical Infrastructure

With the global psychedelic drugs market projected to reach $8.75 billion by 2031, growing at a CAGR of 13.55%, companies controlling standardized pharmaceutical manufacturing and intellectual property are best positioned to generate durable enterprise value.¹

• Hospital pharmacies managed nearly 60% of psychedelic drug distribution in 2025, underscoring the importance of pharmaceutical-grade supply chains.²
• Major pharmaceutical companies have entered the sector through compound acquisitions rather than clinic-based models.³
• GMP standards and IP protection continue to create meaningful competitive barriers.
• Regulatory-compliant traceability systems reduce variability risk and support scalable distribution.

Through its investment in PsyLabs, Psyence BioMed has secured GMP-compliant production capabilities across both psilocybin and ibogaine, supporting clinical continuity while preparing for future commercial-scale supply.

“In emerging therapeutic categories, infrastructure is strategy,” said Aufrichtig. “Our investment in PsyLabs reinforces our commitment to building Psyence BioMed on a durable pharmaceutical foundation. We believe long-term growth will favor companies that prioritize operational discipline and regulatory-grade standards.”

He added, “I believe the strongest companies are built on the right foundations long before their moment arrives, by focusing on fundamentals and preparing carefully for what lies ahead.”

Financial Strength and Growth Positioning

Psyence BioMed is executing its strategy from a position of financial stability. The Company is well capitalized, carries no corporate debt, and is supported by an experienced executive team advancing an integrated psilocybin and ibogaine development strategy under a clear regulatory and commercialization roadmap.

As institutional investors increasingly assess infrastructure-backed psychedelic platforms, Psyence BioMed believes its alignment with PsyLabs enhances its competitive positioning within the sector and supports long-term shareholder value creation.

Changes to the Management Team

Effective February 20, 2026, Seth Feuerstein resigned as a director of the Company. The resulting vacancy has been filled by the appointment of Sashank Pillay. Mr. Pillay has served as country manager and community and government relations liaison for governmentally licensed psilocybin cultivation and production facilities in Southern Africa. Following the Company's sizable investment in PsyLabs, the Company welcomes Mr. Pillay to the Board of Directors and believes his position on the Board shall be valuable to the Company given his experience in cultivation and production project execution, design, construction, operations management and logistics, and knowledge of international controlled substance regulatory frameworks, quality management, logistics and supply chain management and customs and import/export facilitation.

Learn more at http://www.psyencebiomed.com and on LinkedIn.

Contact Information for Psyence Biomedical Ltd. 
Email: ir@psyencebiomed.com   
Media Inquiries: media@psyencebiomed.com  
General Information: info@psyencebiomed.com  

Investor Contact: 
Michael Kydd 
Investor Relations Advisor 
michael@psyencebiomed.com  

Forward Looking Statements 

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning. 

Forward-looking statements in this communication include statements regarding the sustained execution and long-term competitiveness of the Company, the operational and commercially readiness of the Company's vertically integrated model, the reduction of strategy execution risk, and the advancement of the Company's product and clinical development programme. These statements are based on current assumptions and expectations, including assumptions that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, the Company will retain all such regulatory and other consents required to complete the trial, PsyLabs will maintain its production standards, and the demand for psychedelic-assisted therapy will continue to increase. These assumptions may prove incorrect. There can be no assurance as to when a share consolidation will be implemented, if at all. There are numerous risks and uncertainties that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, among others: (i) the Company’s ability to maintain compliance with Nasdaq’s continued listing standards; (ii) potential volatility in the Company’s share price; (iii) changes in the regulatory, competitive, and economic landscape; and (iv) risks associated with the Company’s development plans and clinical trials. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC. 

These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements. 

The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations. 

¹ Mordorintelligence.com
² Mordorintelligence.com
³ Stat +

FAQ

What did PBM announce on March 11, 2026 about PsyLabs and clinical exports?

Psyence BioMed announced PsyLabs exported its first clinical-trial product to Australia, showing operational capability. According to the company, this export supports that its vertically integrated GMP supply chain is commercially ready and aligned with ongoing Phase IIb clinical activity.

How does the PsyLabs investment affect PBM's manufacturing capabilities and supply chain?

The investment gives PBM licensed, GMP-compliant manufacturing and in-house analytical labs. According to the company, controlling production, quality, and regulatory supply materially reduces execution risk and readies the firm for clinical continuity and future commercial-scale supply.

What is PBM's stated financial position and capital strategy as of March 11, 2026?

PBM says it operates with disciplined capital allocation and carries no corporate debt. According to the company, equity issuance is used selectively, executive pay is performance-aligned, and spending prioritizes clinical and manufacturing investment over promotion.

Who joined PBM's board following the PsyLabs investment and why is that significant?

PBM appointed Sashank Pillay to the board after a director resignation, bringing cultivation and production operations experience. According to the company, his expertise in cultivation, regulatory frameworks, and logistics supports PsyLabs operational and international supply considerations.